St. Jude wins CE mark for hypertension treatment device

The race to launch new cardiac rhythm management devices continues. This time, St. Jude Medical ($STJ) is rolling out its EnligHTN renal denervation system in Europe, following CE mark approval. The device uses a number of electrodes and radiofrequency energy to selectively sear, or disable, renal nerves traveling from the arteries to the kidneys, with the goal of treating hypertension for patients who haven't responded to other, more traditional treatments, Bloomberg explains. Competition will be, well, fierce, the article reminds us, with rivals in the space including Medtronic ($MDT), Covidien ($COV) and Vessix Vascular. Story

Suggested Articles

AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.